United States Investigational Site
Spartanburg, South Carolina, United States
NCT Number: NCT00465959
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
Looking for future studies?
Notify Me40 year–80 year
All sexes
Interventional
Phase 1 / Phase 2
Spartanburg, South Carolina, United States
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Endo USA Inc., a Keenova Therapeutics Company
Industry
Safety, Tolerability, Pharmacokinetics, and Efficacy of Single Inhaled Administrations of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02811588
Chronic Disease, Chronic Obstructive Pulmonary Disease
Aachen, North Rhine-Westphalia, Germany
View Trial DetailsNCT03566667
Chronic Disease, Chronic Obstructive Pulmonary Disease
Örebro, Sweden
View Trial DetailsNCT01245569
Chronic Disease, Chronic Obstructive Pulmonary Disease
Aarhus, Denmark
View Trial DetailsNCT05775588
Chronic Disease, Chronic Obstructive Pulmonary Disease
Beijing, Beijing Municipality, China
View Trial Details